Abstract:The artificial pancreas (AP) system is designed to regulate blood glucose in subjects with type 1 diabetes using a continuous glucose monitor informed controller that adjusts insulin infusion via an insulin pump. However, current AP developments are mainly hybrid closed-loop systems that include feed-forward actions triggered by the announcement of meals or exercise. The first step to fully closing the loop in the AP requires removing meal announcement, which is currently the most effective way to alleviate po… Show more
“…Regarding the meals, even though MPC-based AP is naturally robust to bad announced meals, studies have revealed that its performance is significantly degraded when the size of meals increases [37]. To deal with this condition, two augmented doubleintegrator observers are proposed to have an offset-free behavior under both, partially-announced and unannounced meals scenarios, as well as to cope with moderate plant-model uncertainties.…”
“…Regarding the meals, even though MPC-based AP is naturally robust to bad announced meals, studies have revealed that its performance is significantly degraded when the size of meals increases [37]. To deal with this condition, two augmented doubleintegrator observers are proposed to have an offset-free behavior under both, partially-announced and unannounced meals scenarios, as well as to cope with moderate plant-model uncertainties.…”
“…Current artificial pancreas systems also have several challenges that need to be addressed if they are to be used in conjunction with bioelectronic medicine. Among them, the delays in interstitial glucose sensing and hormonal subcutaneous absorption (Ramli et al 2019;Taleb et al 2019;Gingras et al 2018;Herrero et al 2017), failures in the insulin pump (Meneghetti et al 2018), and glycaemic control during meals (Ramkissoon et al 2018) and exercise (Ramkissoon et al 2020) are the most critical. Despite these challenges, the use of the artificial pancreas is associated with high levels of satisfaction and quality of life, and reduced fear of hypoglycaemic events among the users (Ramli et al 2019).…”
Modulation of the nervous system by delivering electrical or pharmaceutical agents has contributed to the development of novel treatments to serious health disorders. Recent advances in multidisciplinary research has enabled the emergence of a new powerful therapeutic approach called bioelectronic medicine. Bioelectronic medicine exploits the fact that every organ in our bodies is neurally innervated and thus electrical interfacing with peripheral nerves can be a potential pathway for diagnosing or treating diseases such as diabetes. In this context, a plethora of studies have confirmed the important role of the nervous system in maintaining a tight regulation of glucose homeostasis. This has initiated new research exploring the opportunities of bioelectronic medicine for improving glucose control in people with diabetes, including regulation of gastric emptying, insulin sensitivity, and secretion of pancreatic hormones. Moreover, the development of novel closed-loop strategies aims to provide effective, specific and safe interfacing with the nervous system, and thereby targeting the organ of interest. This is especially valuable in the context of chronic diseases such as diabetes, where closed-loop bioelectronic medicine promises to provide real-time, autonomous and patient-specific therapies. In this article, we present an overview of the state-of-the-art for closed-loop neuromodulation systems in relation to diabetes and discuss future related opportunities for management of this chronic disease.
“…Where a truly closed-loop system could deliver insulin autonomously, the hybrid system still works best when the user alerts the insulin pump before eating and gives themselves a dose of insulin to cover the food that will be consumed (FDA, 2018b). Although, research has shown that the system is capable of adjusting the prandial dose to cover a meal, currently available short-acting insulin does not act rapidly enough to maintain the appropriate blood glucose level after a meal (Ramkissoon, Herrero, Bondia, & Vehi, 2018).…”
The hybrid closed-loop insulin delivery system, a form of "artificial pancreas," is composed of an insulin pump, a standardized algorithm, and a continuous glucose monitor. The system streamlines insulin delivery by connecting continuous glucose monitor data with an insulin pump and an algorithm to drive basal insulin delivery. The hybrid closed-loop insulin delivery system, approved by the Food and Drug Administration in 2016 for children older than 7 years, is a major improvement in the management of type 1 diabetes. The purpose of this article is to educate school nurses about the components of the hybrid closed-loop insulin delivery system, the relevance to care, and the future direction of blood glucose management.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.